Skip to content
value.today

Crescent Biopharma, Inc.: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value

Free cash flow over the last three years averaged below zero, so a cash-flow value cannot be worked out.

Price to salesPrice to sales of Biotechnology: $24 M to $110 M, median $54 MPrice to bookPrice to book of Biotechnology: $621 M to $2.6 B, median $912 M$0 M$707 M$1.4 B$2.1 B$2.8 B

Your own DCF model

A full discounted-cash-flow model of Crescent Biopharma, Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Biotechnology

Multiples of its companies with a market value at most 60 days old, times Crescent Biopharma, Inc.'s own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)Crescent Biopharma, Inc.Applied toValue (25th to 75th)Companies
Price to sales2.2× / 5.0× / 10.2×—revenue $11 M$24 M to $110 M84
Price to book3.1× / 4.5× / 12.9×—book equity $203 M$621 M to $2.6 B69

Against its own history

Crescent Biopharma, Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Jun 2025, each against its own median.

Price to book

0.5×

Now below its median of 0.8×, in the bottom quarter of its range; range 0.4× to 4.5× over 10 months.

0×1×2×3×5×202020212022202320242025Price to book 0×Median 1×

As of Jun 17, 2025

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Dec 31, 2025$11 M$-154 M$-72 M$1 M$-72 M—SEC annual report (10-K, 20-F)
FY2024to Dec 31, 2024—$-38 M$-31 M$0 M$-31 M—SEC annual report (10-K, 20-F)
FY2023to Dec 31, 2023$0 M$-37 M$-35 M$0 M$-35 M—SEC annual report (10-K, 20-F)
FY2022to Dec 31, 2022$0 M$-47 M$-46 M$0 M$-47 M—SEC annual report (10-K, 20-F)
FY2021to Dec 31, 2021$1 M$-63 M$-57 M$0 M$-58 M—SEC annual report (10-K, 20-F)
FY2020to Dec 31, 2020$10 M$-51 M$-39 M$0 M$-39 M—SEC annual report (10-K, 20-F)